— Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported earnings of 69 cents per share during fiscal year 2019, compared to a loss of 65 cents per share a year ago.
— For the full year, revenue rose to $168.7 million, vs. $16.1 million last year.
— During Q4, the company started dosing patients in an adaptive design Phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registrational study of ARO-AAT.
— ARWR shares have more-than-quadrupled since the beginning of this year.
Seagate Technology plc (NASDAQ: STX), a leading provider of data storage solutions, Thursday said its earnings declined in the first quarter of 2021, owing to a 10% fall in revenues.
Intel Corporation (NASDAQ: INTC) reported third quarter 2020 earnings results today. Revenue fell 4% year-over-year to $18.3 billion. GAAP net income decreased 29% to $4.3 billion while EPS dropped 25%
AT&T Inc. (NYSE: T) today reported its third quarter financial results for the period ended September 30, 2020. Net income for the third quarter was $2.8 billion, or $0.39 per